ArticleCancer science2020

Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts.

Yung-Jue Bang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.